Total Payments
$14,914
2024 Payments
$2,365
Companies
59
Transactions
1,096
Medicare Patients
1,669
Medicare Billing
$382,377
Payment Breakdown by Category
Food & Beverage$14,602 (97.9%)
Education$312.07 (2.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $14,602 | 1,077 | 97.9% |
| Education | $312.07 | 19 | 2.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,945 | 194 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,224 | 94 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,080 | 57 | $0 (2024) |
| Novo Nordisk Inc | $1,017 | 68 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $962.15 | 39 | $0 (2024) |
| ITI, Inc. | $869.49 | 51 | $0 (2023) |
| PFIZER INC. | $839.02 | 87 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $838.04 | 48 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $693.32 | 59 | $0 (2024) |
| Allergan, Inc. | $683.25 | 83 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,365 | 143 | ABBVIE INC. ($495.93) |
| 2023 | $2,298 | 145 | AbbVie Inc. ($443.40) |
| 2022 | $2,344 | 167 | ABBVIE INC. ($540.55) |
| 2021 | $2,853 | 194 | AbbVie Inc. ($451.16) |
| 2020 | $1,466 | 116 | Allergan, Inc. ($252.31) |
| 2019 | $1,539 | 143 | PFIZER INC. ($220.90) |
| 2018 | $1,059 | 91 | Allergan Inc. ($200.19) |
| 2017 | $988.27 | 97 | PFIZER INC. ($160.15) |
All Payment Transactions
1,096 individual payment records from CMS Open Payments — Page 1 of 44
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $25.26 | General |
| Category: PSYCHIATRY | ||||||
| 12/18/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $10.34 | General |
| Category: Diabetes | ||||||
| 12/17/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.50 | General |
| Category: NEUROSCIENCE | ||||||
| 12/09/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: Neuropsychiatry | ||||||
| 12/04/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.91 | General |
| Category: NEUROSCIENCE | ||||||
| 12/03/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/03/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.21 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.36 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: Neuropsychiatry | ||||||
| 11/14/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $24.02 | General |
| Category: PSYCHIATRY | ||||||
| 11/14/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $19.42 | General |
| Category: GI | ||||||
| 11/11/2024 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $16.51 | General |
| Category: Addiction Medicine | ||||||
| 11/07/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.05 | General |
| Category: NEUROSCIENCE | ||||||
| 11/05/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $23.99 | General |
| Category: PSYCHIATRY | ||||||
| 10/31/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: Obesity | ||||||
| 10/30/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $5.93 | General |
| Category: Obesity | ||||||
| 10/28/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: NEUROSCIENCE | ||||||
| 10/28/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $2.04 | General |
| Category: NEUROSCIENCE | ||||||
| 10/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.78 | General |
| Category: NEUROSCIENCE | ||||||
| 10/22/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $26.08 | General |
| Category: PSYCHIATRY | ||||||
| 10/22/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $12.83 | General |
| Category: VACCINES | ||||||
| 10/18/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $7.66 | General |
| Category: RESPIRATORY | ||||||
| 10/17/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: VACCINES | ||||||
| 10/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: Neuropsychiatry | ||||||
| 10/16/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $4.44 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 224 | 3,634 | $116,458 | $44,653 |
| 2022 | 11 | 273 | 8,670 | $161,664 | $60,386 |
| 2021 | 11 | 466 | 15,992 | $320,656 | $123,432 |
| 2020 | 14 | 706 | 14,255 | $447,781 | $153,906 |
Total Patients
1,669
Total Services
42,551
Medicare Billing
$382,377
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 47 | 281 | $62,303 | $25,448 | 40.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 33 | 80 | $23,738 | $9,862 | 41.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 28 | 28 | $6,453 | $3,309 | 51.3% |
| 20552 | Injection of trigger points, 1-2 muscles | Office | 2023 | 14 | 80 | $9,251 | $3,051 | 33.0% |
| 98927 | Osteopathic manipulative treatment, 5-6 body regions | Office | 2023 | 18 | 35 | $4,259 | $1,460 | 34.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 14 | 61 | $3,112 | $614.80 | 19.8% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 32 | 32 | $1,170 | $551.36 | 47.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 13 | 192 | $2,880 | $167.44 | 5.8% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2023 | 14 | 320 | $1,600 | $134.52 | 8.4% |
| J1071 | Injection, testosterone cypionate, 1 mg | Office | 2023 | 11 | 2,525 | $1,692 | $54.07 | 3.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 53 | 396 | $87,801 | $35,036 | 39.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 36 | 58 | $17,210 | $7,761 | 45.1% |
| 98927 | Osteopathic manipulative treatment, 5-6 body regions | Office | 2022 | 38 | 181 | $22,024 | $7,385 | 33.5% |
| 20552 | Injection of trigger points, 1-2 muscles | Office | 2022 | 23 | 118 | $13,646 | $4,628 | 33.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 20 | 20 | $4,610 | $2,488 | 54.0% |
| 99497 | Advance care planning, first 30 minutes | Office | 2022 | 18 | 18 | $3,017 | $1,167 | 38.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 15 | 109 | $5,561 | $1,145 | 20.6% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 21 | 21 | $767.76 | $362.25 | 47.2% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2022 | 23 | 472 | $1,064 | $203.33 | 19.1% |
| J1071 | Injection, testosterone cypionate, 1 mg | Office | 2022 | 14 | 7,201 | $4,825 | $149.78 | 3.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 12 | 76 | $1,140 | $61.17 | 5.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 75 | 362 | $107,413 | $43,608 | 40.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 69 | 422 | $93,566 | $41,333 | 44.2% |
| 98927 | Osteopathic manipulative treatment to 5-6 body regions | Office | 2021 | 61 | 372 | $45,265 | $16,490 | 36.4% |
| 20552 | Injections of trigger points in 1 or 2 muscles | Office | 2021 | 40 | 205 | $23,706 | $8,552 | 36.1% |
About Dr. Michael Septer, D.O
Dr. Michael Septer, D.O is a Family Medicine healthcare provider based in Grand Rapids, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1013908060.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Septer, D.O has received a total of $14,914 in payments from pharmaceutical and medical device companies, with $2,365 received in 2024. These payments were reported across 1,096 transactions from 59 companies. The most common payment nature is "Food and Beverage" ($14,602).
As a Medicare-enrolled provider, Septer has provided services to 1,669 Medicare beneficiaries, totaling 42,551 services with total Medicare billing of $382,377. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Grand Rapids, MI
- Active Since 10/31/2005
- Last Updated 08/13/2025
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1013908060
Products in Payments
- VRAYLAR (Drug) $1,960
- CAPLYTA (Drug) $1,221
- REXULTI (Drug) $1,035
- TRELEGY ELLIPTA (Drug) $738.46
- STIOLTO RESPIMAT (Drug) $734.67
- CHANTIX (Drug) $498.86
- TROKENDI XR (Drug) $429.73
- Ozempic (Drug) $397.77
- BREZTRI (Drug) $329.23
- SYMBICORT (Drug) $327.02
- TRULICITY (Drug) $252.08
- SPIRIVA RESPIMAT (Drug) $216.82
- Rybelsus (Drug) $210.21
- Zubsolv (Drug) $206.39
- TRINTELLIX (Drug) $190.77
- ANORO ELLIPTA (Drug) $187.99
- LINZESS (Drug) $185.52
- Wegovy (Drug) $184.03
- Aimovig (Biological) $180.95
- Amitiza (Drug) $178.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Grand Rapids
Mary Dagen, M.d, M.D
Family Medicine — Payments: $162,324
Family Medicine $162,324
Oren Mason, M.d, M.D
Family Medicine — Payments: $118,364
Family Medicine $118,364
Magalis Llovet, Md, MD
Family Medicine — Payments: $21,470
Family Medicine $21,470
Dr. Monica Schmidt, D.o, D.O
Family Medicine — Payments: $17,790
Family Medicine $17,790
Dr. Stephen Cahill, D.o, D.O
Family Medicine — Payments: $14,765
Family Medicine $14,765
Dr. Jeffrey Vanwingen, M.d, M.D
Family Medicine — Payments: $13,853
Family Medicine $13,853